1.             M. Upendra Rao, M. Sreenivasulu, B. Chengaiah, K. Jaganmohan Reddy, C. Madhusudhana Chetty. Herbal Medicines for Diabetes Mellitus: A Review, International Journal of PharmTech Research, 2010; Vol.2, No.3, pp 1883-1892.

2.             Shikha Srivastava, Vijay Kumar Lal, Kamlesh Kumar Pant. Polyherbal formulations based on Indian medicinal plants as antidiabetic Phytopharmacology. 2012; 2(1) 1-15.

3.             Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, Hellman R, Jellinger PS, Jovanovic LG, Levy P, Mechanick JI, Zangeneh F; AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13 Suppl 1:1-68.

4.             Azizi F, Guoya MM, Vazirian P, Dolatshati P, Habbibian S. Screening for type 2 diabetes in the Iranian national programme: a preliminary report. East Mediterr Health J 2003;9(5-6):1122-7.

5.             Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27(5):1047-53.

6.             http://www.annals.org/site/misc/about.xhtml

7.             http://www.archive.org/stream/ondiabetesmelli00kleegoog/ondiabetesmelli00kleegoog_djvu.t xt

8.             Ross and Wilson. Anatomy and Pathophysiology in Health and Illness, Churchill Livingstone Elsevier, 11th edition, 2010, 227-229.

9.             Alemu S, Dessie A, Seid E. Insulin-requiring diabetes in rural Ethiopia: should we reopen the case for malnutritionrelated diabetes, Diabetologia. 2009; 52:1842-1845

10.         Wild S, Roglic G, Green A, Sicree R, King. Global prevalence of diabetes: Estimates for the year 2000and projections for 2030, Diabetes Care. 2004; 27:1047-53.

11.         Gupta OP, Joshi MH, Daves SK. Prevalence of Diabetes in India, Adv Metab Disord. 1978; 9:147-65.

12.         Alemu S, Dessie A, Seid E. Insulin-requiring diabetes in rural Ethiopia: should we reopen the case for malnutritionrelated diabetes, Diabetologia. 2009; 52:1842-1845

13.         Gupta OP, Joshi MH, Daves SK. Prevalence of Diabetes in India, Adv Metab Disord. 1978; 9:147-65.

14.         Bordoloi R, Dutta KN. A Review on Herbs Used in the Treatment of Diabetes mellitus.Journal of Pharmaceutical,Chemical and Biological. Sciences;2014(2):86–92.

15.         Malvi R, Jain S, Khatri S, Patel A, Mishra S. A Review on Antidiabetic Medicinal Plants and Marketed Herbal For mulations. International Journal of Pharmaceutical & Biological Archives;2011(2):1344–1355.

16.          Rahimi M. A Review: Anti Diabetic medicinal plants used for diabetes mellitus. Bulletin of environmental, pharmacology and life. sciences;2015(4):163–180.

17.          Mishra R, Shuaib M, Shravan M, S P. A review on herbal antidiabetic drugs. Journal of Applied Pharmaceutical Science2011;1(6):235–237.

18.         Rahimi M. A Review: Anti Diabetic medicinal plants used for diabetes mellitus. Bulletin of environmental, pharma- cology and life. sciences;2015(4):163–180.

19.         Dwivedi CP, Daspaul S. Antidiabetic herbal drugs and polyherbal formulation used for diabetes: A review. The journal of phytopharmacology;2013(2):44–51.

20.         Addae M.I., Achenbach H.: Phytochemistry 24, 1817 (1985).

21.         Sokeng S.D., Rokeya B., Mostafa M., et al.: Afr. J. Tradit. Complement. Altern. Med. 2, 94 (2005).

22.         Punitha I.S.R., Rajendran K., Shirwaikar A., et al.: Alternat. Med. 2, 375 (2005).

23.         Pearson, M.J.; Unger, R.H.; Holland, W.L. Clinical Trials, Triumphs, and Tribulations of Glucagon Receptor Antagonists. Diabetes Care 2016, 39, 1075–1077

24.         Scheen, A.J.; Paquot, N.; Lefèbvre, P.J. Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes. Expert. Opin. Investig. Drugs 2017, 26, 1373–1389.

25.         Chen, Y.-S.; Weng, S.-J.; Chang, S.-H.; Li, R.-Y.; Shane, G.-T.; Hsu, J.-P.; Yeh, S.-W.; Chang, A.-C.; Lee, M.-J.E. Evaluating the antidiabetic effects of R-verapamil in type 1 and type 2 diabetes mellitus mouse models. PLoS ONE 2021, 16, e0255405.

26.         Klec, C.; Ziomek, G.; Pichler, M.; Malli, R.; Graier, W.F. Calcium Signaling in ß-cell Physiology and Pathology: A Revisit. Int. J. Mol. Sci. 2019, 20, 6110

27.         Andersson, D.E.; Röjdmark, S. Blood glucose lowering effect of verapamil in fasted man. Horm. Metab. Res. 1984, 16 (Suppl. S1), 160–163

28.         Fadda, G.Z.; Hajjar, S.M.; Zhou, X.J.; Massry, S.G. Verapamil corrects abnormal metabolism of pancreatic islets and insulin secretion in phosphate depletion. Endocrinology 1992, 130, 193–202.

29.         Jahan, I.; Corbin, K.L.; Bogart, A.M.; Whitticar, N.B.; Waters, C.D.; Schildmeyer, C.; Vann, N.W.; West, H.L.; Law, N.C.; Wiseman, J.S.; et al. Reducing Glucokinase Activity Restores Endogenous Pulsatility and Enhances Insulin Secretion in Islets From db/db Mice. Endocrinology 2018, 159, 3747–3760.

30.         Tuso P. Prediabetes and lifestyle modification: time to prevent a preventable disease. Perm J (2014) 18(3):88–93. doi:10.7812/TPP/14-002

31.         (2016). Available from: http://care.diabetesjournals.org/content/39/ Supplement_1

32.         Riser Taylor S, Harris KB. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2diabetes mellitus. Pharmacotherapy (2013) 33(9):984–99. doi:10.1002/phar.1303

33.         . Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes (2002) 51(3):5368–76. doi:10.2337/diabetes.51.2007.S368